Bengü Mutlu Sütcüoğlu, Hatice Kansu Çelik, Emre Akarsu
Journal of Current Hematology & Oncology Research - 2026;4(1):27-30
Cervical leiomyosarcoma and cervical carcinosarcoma are extremely rare malignancies, and optimal management strategies remain undefined. In early-stage disease, the benefit of adjuvant therapy is controversial, raising concerns about potential overtreatment. We report two patients with early-stage primary cervical sarcomas who presented with similar clinical findings but were diagnosed with different histopathological subtypes. A 47-year-old woman presented with abnormal vaginal bleeding and a polypoid cervical mass and was diagnosed with cervical leiomyosarcoma following complete excision. A 66-year-old postmenopausal woman presented with postmenopausal bleeding and was diagnosed with cervical carcinosarcoma after comprehensive surgical staging. In both cases, preoperative imaging demonstrated disease confined to the cervix, and final pathology confirmed FIGO stage IB2 tumors with negative surgical margins and no lymph node or distant metastases. Multidisciplinary tumor board evaluation was performed, and adjuvant chemotherapy or radiotherapy was not administered in either patient. Despite the aggressive histological features traditionally associated with these tumor types, both patients achieved sustained long-term disease-free survival at 2 and 4 years of follow-up, respectively. These cases suggest that selected patients with early-stage cervical sarcomas may achieve favorable outcomes with surgery alone and support a risk-adapted, individualized approach to adjuvant treatment decisions to avoid potential overtreatment.
